The ABL Lyon site is located in Gerland Bio-Disctict in South of Lyon and has been integrated to the ABL manufacturing network in 2018. The site covers 6500 sq meters of lab, offices and technical areas including 750sq meters GMP manufacturing suites, 100m² development areas for USP and DSP, 110m² of control quality lab.
 
The site is specialized in Process Development and Manufacturing of GMP batches for clinical supply (PhI-PhII) of Viral Vectors. The site offers flexibility to adapt to different stage of your project and accelerate its development with several features :

  • High throughput process development with Ambr250® platform, multiple 2L-single use bioreactors and advanced testing capabilities (incl. dPCR).
  • Manufacturing of GMP cell banks and seed lots in dedicated areas
  • 3 GMP suites fully independent (dedicated WFI distribution loops and HVAC system) and equipped with single-use 50L-scale (rocking-motion bioreactors) to 200L-scale (stirred bioreactors) that fit with adherent and suspension cell culture
  • Manual aseptic filling in glass vials and Visual Inspection up to 500 units/batch 

Our team of experts bring extensive experience in viral vectors field with specific focus on AAV process optimization and VERO cells-based process industrialization.

200L
Single use technology

Suite 1 : Grade A / B / C. 
Suspended & adherent (microcarriers)

200L
Single use technology

Suite 2 : Grade A / C. 
Suspended & adherent (microcarriers)

200L
Single use technology

Suite 3 : Grade A / C.
Suspended & adherent (microcarriers)
Operational in 2024

Process development & analytical laboratories

Up to
500 vials
per batch

DP manual filling in grade A / B

317 Avenue Jean Jaurès
69007 Lyon FRANCE
Phone: +33 3 88 55 10 00

CONTACT US

VIRTUAL VISIT

Inspection history

ABL is inspected routinely by the French National Agency for the Safety of Medicines and Health (ANSM), approved and GMP licensed in accordance with EMA (available from EudraLex).

Last ANSM (French National Agency for the Safety of Medicines and Health) inspections:
No critical observation reported

INSPECTION & DATE FEEDBACK
JULY 2020
Routine inspection
No critical observation
JULY 2018
GMP License transfer to ABL Europe
Gene Therapy products added
MARCH 2019
SEPTEMBRE 2017
Routine inspection
No critical observation
Powered by